Janssen Pharmaceutica Nv

Pascal Bonaventure

Curt A Dvorak

Timothy W Lovenberg

Dale A Rudolph

Changlu Liu

Chandravadan R Shah

Nicholas I Carruthers

Brock T Shireman

Wenying Chai

Devin M Swanson

Jill A Jablonowski

Mark Seierstad

Victoria Wong

Steven W Sutton

Jonathan Edward Shelton

Chester Kuei

Diane Nepomuceno

Christine Dugovic

Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin reuptake inhibitor.

Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility. The compounds of the present invention are of the formula where Ring T is a heterocycloalkyl ring selected from the group consisting of: 

Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor

Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.

Relaxin-3 chimeric polypeptides and their preparation and use

Canine 5-hydroxytryptamine 2 receptor materials are described, including polypeptides corresponding to SEQ ID NOs.:8 and 10 and polynucleotides expressing them corresponding to SEQ ID NOs.:7 and 9. Such materials are useful as reagents in drug screening assays to identify compounds having 5-HTreceptor-modulating activity.

Canine 5-hydroxytryptamine 2A and 2B receptor

Growing community of inventors

San Diego, CA, United States of America

Pascal Bonaventure